Norges Bank’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-116,400
Closed -$1.71M 1890
2023
Q4
$1.71M Buy
+116,400
New +$1.78M ﹤0.01% 1806
2023
Q3
Sell
-84,100
Closed -$1.81M 1969
2023
Q2
$1.81M Sell
84,100
-7,800
-8% -$211K ﹤0.01% 1880
2023
Q1
$2.7M Buy
91,900
+10,700
+13% +$372K ﹤0.01% 1883
2022
Q4
$3M Buy
+81,200
New +$2.88M ﹤0.01% 1906

Other funds holding AMLX

Norges Bank's AMLX Position: Q1 2024 in Review

Norges Bank sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 116,400 shares — an estimated $1.71M sold.

Norges Bank first reported a position in AMLX in Q4 2022 and held it in 4 quarters. The position peaked at $3M in Q4 2022. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Norges Bank reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Norges Bank sold 116,400 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $1.71M.
  • Norges Bank first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Norges Bank's Amylyx Pharmaceuticals position peaked at $3M in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Norges Bank's 13F filing for Q1 2024, filed 14 May 2024.